Clinical Trials Directory

Trials / Completed

CompletedNCT04821297

Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results

An Innovative and Linguistically-Tailored Mobile Intervention to Improve Follow-Up for Abnormal Pap Test Results: CervixChat

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Thomas Jefferson University · Academic / Other
Sex
Female
Age
21 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This clinical trial evaluates the feasibility of a linguistically-tailored mobile intervention, called CervixChat in improving the follow-up of patients with abnormal Papanicolaou (pap) test results. A text messaging program, such as CervixChat may support patients who need a colposcopy.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate the feasibility of CervixChat intervention in a mix method design, through participants consent rate and the study completion rate. SECONDARY OBJECTIVE: I. To evaluate the acceptability of CervixChat intervention using a validated Likert-scale participant satisfaction questionnaire, as well as participant's interview data. EXPLORATORY OBJECTIVE: I. To evaluate the preliminary impact of CervixChat intervention, by comparing the colposcopy appointment adherence rate in the study cohort against a 1:1 matched control sample selected based on matching age, race and ethnicity, from participants at Jefferson Obstetrics and Gynecology (Ob-Gyn) department scheduled for a colposcopy in 2019. OUTLINE: Patients receive text messages for 1-2 months before scheduled appointment. Patients also complete a survey at baseline and after standard of care colposcopy and an interview after standard of care colposcopy. After completion of study, patients are followed up periodically.

Conditions

Interventions

TypeNameDescription
OTHERHealth Promotion and EducationReceive messages
OTHERSurvey AdministrationComplete survey
OTHERInterviewParticipate in an interview

Timeline

Start date
2021-02-18
Primary completion
2021-08-31
Completion
2021-09-10
First posted
2021-03-29
Last updated
2025-04-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04821297. Inclusion in this directory is not an endorsement.